Publications by authors named "P Suntharasamai"
Article Synopsis
- - The Bangkok Tenofovir Study (BTS) found that daily tenofovir as pre-exposure prophylaxis (PrEP) can lower HIV infection risk by 49% in people who inject drugs, leading to an extension offering participants one year of open-label PrEP.
- - The study included 1,315 eligible participants from the BTS, revealing that 61% chose to start PrEP, with 42% completing 12 months of follow-up and factors like age, heroin use, and prior imprisonment influencing adherence rates.
- - Data was collected through self-interviews every three months, and findings suggest that older age and specific drug use habits correlated with better uptake and adherence to PrEP, promoting the importance of
Background: Rapid easy-to-use HIV tests offer opportunities to increase HIV testing among populations at risk of infection. We used the OraQuick Rapid HIV-1/2 antibody test (OraQuick) in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial among people who inject drugs.
Methods: The Bangkok Tenofovir Study was a randomized, double-blind, placebo-controlled trial.
Objective: To describe participant adherence to daily oral tenofovir in an HIV preexposure prophylaxis (PrEP) trial, examine factors associated with adherence, and assess the impact of adherence on the risk of HIV infection.
Design: The Bangkok Tenofovir Study was a randomized, double-blind, placebo-controlled trial conducted among people who inject drugs, 2005-2012.
Methods: Participants chose daily visits or monthly visits.
Objectives: We examined the causes of hospitalization and death of people who inject drugs participating in the Bangkok Tenofovir Study, an HIV preexposure prophylaxis trial.
Methods: The Bangkok Tenofovir Study was a randomized, double-blind, placebo-controlled trial conducted during 2005 to 2012 among 2413 people who inject drugs. We reviewed medical records to define the causes of hospitalization and death, examined participant characteristics and risk behaviors to determine predictors of death, and compared the participant mortality rate with the rate of the general population of Bangkok, Thailand.
Background: Tenofovir disoproxil fumarate (tenofovir) has been associated with renal dysfunction in people infected with human immunodeficiency virus (HIV) receiving combination antiretroviral therapy. We reviewed data from an HIV preexposure prophylaxis trial to determine if tenofovir use was associated with changes in renal function in an HIV-uninfected population.
Methods: During the trial, 2413 HIV-uninfected people who inject drugs were randomized to receive tenofovir or placebo.